中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (4): 283-287.doi: 10.12144/zgmfskin202504283

• 临床研究 • 上一篇    下一篇

乌帕替尼成功治疗巴瑞替尼治疗无效的重度斑秃二例

袁明珠1,2,李如意1,2,孙毅1,2,张雯1,2   

  1. 1长江大学附属荆州医院，湖北荆州，434020；2湖北省病原真菌感染诊疗临床医学研究中心，湖北荆州，434020
  • 出版日期:2025-04-15 发布日期:2025-04-08

Severe alopecia areata unresponsive to baricitinib susessfully treated with upadacitinib: two cases report

YUAN Mingzhu1,2, LI Ruyi1,2, SUN Yi1,2, ZHANG Wen1,2   

  1. 1 Jingzhou Hospital Affiliated to Yangtze University, Jingzhou 434020, China; 2 Hubei Clinical Research Center for Diagnosis and Treatment of Pathogenic Fungal Infection, Jingzhou 434020, China
  • Online:2025-04-15 Published:2025-04-08

PDF (PC)

19

摘要： 巴瑞替尼已获批治疗重度斑秃，但有些患者效果不佳，有文献报道乌帕替尼对巴瑞替尼治疗无效的斑秃有效。本文报道2例重度斑秃患者接受巴瑞替尼治疗12周无效，后改用乌帕替尼治疗，疗效显著：患者1治疗40周后发量恢复至正常的70%以上，眉毛再生也获得明显改善；患者2治疗16周后发量恢复至正常。本文证实了乌帕替尼在促进毛发再生的有效性，为巴瑞替尼治疗无效的重度斑秃患者提供了新的治疗选择。

关键词: JAK抑制剂, 巴瑞替尼, 乌帕替尼, 斑秃

Abstract: Baricitinib is approved for the treatment of severe alopecia areata, but some patients do not respond well. It has been reported that upadacitinib is effective in the treatment of alopecia areat. We report two cases of severe alopecia areata (AA) patients who received baricitinib for 12 weeks without efficacy , and then switched to upadacitinib treatment, achieving significant therapeutic effects. After 40 weeks of treatment, patient 1’s hair volume returned to over 70% of normal level, and eyebrow regeneration was also improved significantly. Patient 2 returned to normal volume after 16 weeks of treatment. This study confirms the efficacy of upadacitinib in promoting hair regrowth, providing a new treatment option for patients with severe AA patients who have not responded to baricitinib.

Key words: JAK inhibitors, baricitinib, upadacitinib, alopecia areata